Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus for autism spectrum disorder symptoms in tuberous sclerosis complex
jRCT1090220258Recruiting
- Sponsor
- Kunio Yui
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of everolimus in tuberous sclerosis complex (TSC), Autism Spectrum Disorder (ASD) and subependymal giant cell astrocytoma (SEGA), sponsored by Kunio Yui. Primary endpoints: Aberrant Behavior Checklist (ABC), Social Responsiveness Scale (SRS) and 1 more. Started Aug 2016; status: recruiting.
02
Drugs
everolimus
03
Conditions
tuberous sclerosis complex (TSC)Autism Spectrum Disorder (ASD)subependymal giant cell astrocytoma (SEGA)
Beyond the preview
Go deeper on jRCT1090220258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1090220258.